{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:56:20Z","timestamp":1770965780175,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vaccine.2014.07.096","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T19:46:31Z","timestamp":1407872791000},"page":"5436-5446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada"],"prefix":"10.1016","volume":"32","author":[{"given":"Hong Anh T.","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley L.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Strifler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Crowcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances B.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Coyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.07.096_bib0005","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2011.02.058","article-title":"The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease","volume":"29","author":"Harrison","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.07.096_bib0010","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0020","unstructured":"Health Protection Agency UK. Meningococcal disease epidemiological data, 2011."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0025","unstructured":"Newswire Canada. Health Canada Approves Bexsero*, the First Vaccine Available to Prevent Meningococcal Serogroup B (MenB) (1,2) 2013."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0030","unstructured":"Novartis media release. Novartis vaccine Bexsero\u00ae approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis, 2013."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0035","unstructured":"Novartis media release. Novartis supplies MenB vaccine, Bexsero\u00ae, to Princeton University to help protect students from potentially deadly outbreak, 2013."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0040","unstructured":"Novartis media release. Novartis receives EU approval for Bexsero\u00ae, first vaccine to prevent the leading cause of life-threatening meningitis across Europe, 2013."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0050","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0060","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0065","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0070","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies, n.d."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0075","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO Guide for standardisation of economic evaluations of immunization programmes","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0080","doi-asserted-by":"crossref","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making n.d.;32:690\u2013700.","DOI":"10.1177\/0272989X12455463"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0085","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0095","unstructured":"Kimura M, Vesikari T, Prymula R. Persistence of the immune response to an investigational multicomponent meningococcal serogroup B (4CMenB) vaccine following priming in infants or toddlers. 7th World Congr. World Soc. Pediatr. Infect. Dis., Melbourne, Australia: n.d."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0100","article-title":"Final Report to Outcomes from the National Consensus Conference for Vaccine-Preventable Diseases in Canada","author":"Public Health Agency of Canada","year":"2008","journal-title":"Canada Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2009.01.040","article-title":"Improving decision analyses: parent preferences (utility values) for pediatric health outcomes","volume":"155","author":"Carroll","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00006454-200002000-00010","article-title":"Parents\u2019 preferences for outcomes associated with childhood vaccinations","volume":"19","author":"Kuppermann","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00019053-199915040-00004","article-title":"Utility scores for chronic conditions in a community-dwelling population","volume":"15","author":"Mittmann","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s11136-011-9991-7","article-title":"Assessing health-related quality-of-life changes in informal caregivers: an evaluation in parents of children with major congenital anomalies","volume":"21","author":"Poley","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0125","series-title":"Ontario Health Insurance (OHIP) Schedule of Benefits and Fees","author":"Ministry of Health and Long-term Care","year":"2013"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0130","unstructured":"Public Health Agency. Supplement: Guidelines for the Prevention and Control of Meningococcal Disease. Canada Commun Dis Report Rep No 31S1 n.d."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0135","unstructured":"Ontario Drug Benefit Formulary. Ontario Drug Benefit Formulary\/Comparative Drug Index n.d."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0140","first-page":"122","article-title":"Management of a cluster of cases of invasive group C Neisseria meningitidis infections in the Hamilton-Wentworth region \u2013 Ontario","volume":"24","author":"Tolomeo","year":"1998","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0145","unstructured":"Statistics Canada. Consumer Price Index, n.d."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0150","unstructured":"OCCI. Ontario Case Costing Initiative, n. d."},{"key":"10.1016\/j.vaccine.2014.07.096_bib0155","doi-asserted-by":"crossref","first-page":"e1463","DOI":"10.1542\/peds.2012-0175","article-title":"Patterns and costs of health care use of children with medical complexity","volume":"130","author":"Cohen","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1007626510002","article-title":"Herd immunity and herd effect: new insights and definitions","volume":"16","author":"John","year":"2000","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0165","first-page":"43","article-title":"Parents\u2019 utilities for outcomes of occult bacteremia","volume":"154","author":"Bennett","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0170","series-title":"Poster Sess. Present. Meningitis Septicaemia Child. Adults","article-title":"Impact of Quadrivalent Conjugate (MenACWY- CRM) and Serogroup B (4CMenB) Meningococcal Vaccines on Meningococcal Carriage in English University Students","author":"Read","year":"2013"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0175","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1016\/j.vaccine.2013.06.080","article-title":"Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage","volume":"31","author":"Delbos","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.096_bib0180","unstructured":"U.S. Census Bureau. The 2012 Statistical Abstract - Births, Deaths, Marriages, & Divorces: Life Expectancy, 2014."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T21:15:10Z","timestamp":1565730910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14010780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":36,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0264410X14010780"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.096","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2014 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}